RxDoctor Payments Data

Kyle Huynh, MD

Ophthalmology · Camarillo, CANPI 1366861031

Payments from drug & device makers

$5,538in general payments, 2019–2025

Across 81 payments — averaging $68.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$3K
  • Alcon$358
  • Sun Pharmaceutical Industries Inc.$356
  • AbbVie$310
  • Novartis$284
  • Dompe US, Inc.$214
  • plus $1K from 12 others

What the payments were for

  • Speaking & faculty fees$2,00036%
  • Food & beverage$3,53864%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,538 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$435,909
Medicare patients
1,000
Services billed
3,328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj20$893,355
XiidraLifitegrast84$65,929
RestasisCyclosporine50$32,959
CequaCyclosporine11$10,480
Prednisolone Acetate281$10,437
Cyclosporine37$8,617
Tobramycin-DexamethasoneTobramycin/Dexamethasone192$8,321
Dorzolamide-TimololDorzolamide/Timolol/Pf19$3,437
ValacyclovirValacyclovir Hcl47$2,556
Loteprednol Etabonate15$2,337
Brimonidine Tartrate19$1,924
Minocycline Hcl85$1,542
MoxifloxacinMoxifloxacin Hcl68$1,368
Difluprednate11$1,367
Travoprost11$1,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$214$893,35520 claims
Bausch & Lomb Americas Inc.Xiidra$142$65,92984 claims
AbbVieRestasis$310$32,95950 claims
Sun Pharmaceutical Industries Inc.Cequa$356$10,48011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Camarillo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →